Humana Cuts 2026 EPS Guidance to $25.50–$26.00, Shares Drop Over 3%
Humana lowered its 2026 adjusted EPS outlook to $25.50–$26.00, missing the $27.50 analyst consensus and forecasting 400,000 Medicare Advantage enrolment gains instead of the prior 600,000 target, prompting shares to fall over 3%. The insurer reported year-over-year increases in fourth-quarter revenue and operating income, but cautious guidance drove the sell-off.
1. Guidance Revision
Humana trimmed its full-year 2026 adjusted EPS outlook to a range of $25.50–$26.00, well below the $27.50 consensus. Management cited margin pressures and a need for conservative assumptions around benefits costs.
2. Membership Growth Outlook
The company reduced its projected Medicare Advantage membership addition to roughly 400,000 new lives versus the prior 600,000 target, reflecting rising competition and regulatory headwinds. Slower enrolment growth may limit premium revenue expansion.
3. Q4 Results and Market Reaction
Despite reporting year-over-year gains in fourth-quarter revenue and operating income, investors focused on the revised outlook. Humana’s share price slid more than 3% in early trading as market participants adjusted forecasts for 2026.